Is BPC-157 legal? Status by country

The short answer is that BPC-157 is not an approved medicine anywhere we cover. It is not authorised by the FDA, the EMA, the MHRA, or any national medicines agency in the EU or EEA. It sits on the WADA Prohibited List under S0 (non-approved substances), and the US Department of Defense's Operation Supplement Safety programme calls it "a prohibited peptide and an unapproved drug"^[1]. What follows is a jurisdiction-by-jurisdiction breakdown of what that means in practice, what changed in early 2026, and what the upcoming FDA advisory committee meeting could shift.

United States: unapproved, with a pending review

BPC-157 is not FDA-approved for any indication. No new-drug application (NDA) or biologics licence application (BLA) has been submitted for BPC-157, and no completed phase-2 or phase-3 randomised controlled trial supports one^[2]. USADA states plainly that there "appears to be no legal basis for selling BPC-157 as a drug, food, or a dietary supplement"^[2]. The FDA has confirmed there is no legal basis for compounding pharmacies to use it in medications without a change in its regulatory status.

The compounding question is where most of the recent movement has happened. In 2023, the FDA placed BPC-157 on Category 2 of its bulk drug substances list under section 503A of the Federal Food, Drug, and Cosmetic Act. Category 2 is a holding list for substances the FDA has raised safety or eligibility concerns about, and placement on it effectively blocked compounding pharmacies from preparing BPC-157. On 15 April 2026, the FDA removed BPC-157 from Category 2 after the original nominators formally withdrew their nominations^[3].

That removal does not make BPC-157 legal to compound. Because BPC-157 has not been added to Category 1 (the positive list of substances approved for compounding), it sits in a regulatory gap. It is neither explicitly blocked nor explicitly permitted. The practical effect for compounding pharmacies is that prescribing or dispensing BPC-157 still carries the same federal enforcement risks as before the April 2026 change.

The next step is the Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for 23 to 24 July 2026 at the FDA's White Oak Campus in Silver Spring, Maryland. On Day 1, the committee will consider whether BPC-157 (both free base and acetate forms), along with KPV, TB-500 and MOTs-C, should be added to the section 503A positive list. A place on that list would formally authorise licensed compounding pharmacies to prepare BPC-157 for individual patients with prescriptions. The PCAC vote is advisory only. The FDA retains final statutory authority, and a formal rulemaking process would follow any favourable recommendation. Until that process concludes, BPC-157 remains an unapproved new drug under federal law.

European Union and EEA: no marketing authorisation

The European Medicines Agency has not reviewed BPC-157. There is no centralised marketing authorisation, no referral procedure, and no European public assessment report (EPAR). No pharmaceutical company has submitted a marketing authorisation application for BPC-157 to the EMA or to any national competent authority in the EU or EEA.

In practice, each member state applies its own national pharmaceutical law. Because BPC-157 has no marketing authorisation in any EU or EEA country, selling or supplying it for human use falls outside the regulated pharmaceutical framework. It is not a controlled substance under national drug-scheduling laws (it does not appear on UN convention schedules), but that distinction matters less than it sounds. Unauthorised medicines are regulated through medicines law, not through controlled-substance law. The practical effect is that sale and supply for human consumption is prohibited, even if simple possession for personal use is not specifically criminalised in most member states. See the BPC-157 regulation section for per-country detail across Denmark, Sweden, Norway, Germany and the Netherlands.

In several EU countries, national medicines agencies have issued warnings about peptides sold as "research chemicals" for what is clearly intended human use. The labelling of "not for human consumption" or "for research use only" does not create a legal exemption. It is a vendor-side disclaimer that has no standing in EU pharmaceutical law. If a product is sold in a form and at a dose consistent with human administration (a lyophilised vial with reconstitution instructions, for example), regulators can and do treat it as an unauthorised medicinal product regardless of the label.

United Kingdom: unlicensed medicine

The MHRA classifies BPC-157 as an unlicensed medicine. It is not a controlled drug under the Misuse of Drugs Act 1971 and does not fall within the scope of the Psychoactive Substances Act 2016. It is not listed on any MHRA prescription-only medicine or pharmacy-medicine schedule.

What this means in practice: purchasing BPC-157 labelled "for research purposes" is not a criminal offence for the buyer, but marketing or supplying it for human use without marketing authorisation is prohibited under the Human Medicines Regulations 2012. The enforcement gap between these two positions is where the UK grey market operates. Vendors ship BPC-157 from UK addresses to UK customers with a research-use disclaimer while packaging the product in single-use vials with subcutaneous-injection guidance. The MHRA has not launched a public enforcement campaign specifically targeting BPC-157 vendors, but the legal framework is clear: supply for human use without authorisation is an offence.

Sport and military: prohibited across the board

The World Anti-Doping Agency added BPC-157 to its Prohibited List in January 2022 under category S0 (non-approved substances). S0 covers any pharmacological substance that is not approved by a recognised government authority for therapeutic use in humans. The prohibition applies in competition and out of competition, at all times, for all athletes subject to the WADA Code^[2].

USADA has published guidance stating that BPC-157 "is not a legitimate dietary supplement or approved medication" and that "because BPC-157 has not been extensively studied in humans, no one knows if there is a safe dose, or if there is any way to use this compound safely"^[2]. There is no therapeutic use exemption (TUE) pathway for BPC-157, because TUE applications require an approved therapeutic indication, which BPC-157 does not have. The NFL and UFC specifically prohibit it by name; MLB and NCAA include it under broader peptide-hormone restrictions^[3].

For military personnel, the US Department of Defense's Operation Supplement Safety programme classifies BPC-157 as both a prohibited dietary supplement ingredient and an unapproved drug. Service members are warned that military drug policy enforces strict liability for any positive test involving BPC-157, regardless of intent or awareness^[1]. Detection is possible: testing shows BPC-157 is detectable in urine for at least 72 hours after administration^[3].

What this is not

This article is not a forecast of the PCAC outcome. The July 2026 meeting may result in a recommendation for or against adding BPC-157 to the 503A positive list, but the committee's vote is advisory, and final FDA rulemaking would follow on a separate timeline. Even a favourable decision would not grant marketing authorisation as a new drug. It would permit licensed compounding pharmacies to prepare BPC-157 for individual patients with prescriptions, subject to the quality and labelling requirements of 503A compounding. The new-drug approval pathway (NDA or BLA) is a separate and much longer process that would require completed human clinical trials.

This article is also not a guide to purchasing BPC-157. The grey-market supply labelled "for research use only" exists in every jurisdiction we cover, and independent testing of those products has repeatedly flagged purity, identity and contamination failures. Vials have been found containing the wrong molecule entirely, with purity well below the labelled figure, or with bacterial endotoxin levels exceeding pharmaceutical limits. That supply chain is not regulated, not pharmaceutical-grade, and not the same thing as a compounded or approved medicine. If you already have a product, the quality-verification guidance on the BPC-157 peptide page covers what to look for and what to walk away from.

Where this leaves readers

The regulatory picture as of mid-2026 is settled on one point and unsettled on another. The settled point: BPC-157 is not an approved medicine anywhere, and that fact has not changed since its isolation in 1991. No jurisdiction we cover authorises it for human therapeutic use. The unsettled point: the US compounding pathway is actively being reviewed, and the PCAC meeting in July 2026 may shift the landscape for 503A pharmacies specifically. We will update this page when the committee reports.

If you are considering BPC-157, the conversation about whether to use it belongs with a clinician who knows your medical history, not with a vendor or an internet forum. For the full peptide profile, the state of the animal evidence, supply-quality guidance and country-by-country regulation detail, see the BPC-157 peptide page.